Skip to main content
Clinical Trials/NCT02259192
NCT02259192
Unknown
N/A

Cochlear Implantation for Single-Sided Deafness

Robert Shannon2 sites in 1 country10 target enrollmentSeptember 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Single-sided Deafness
Sponsor
Robert Shannon
Enrollment
10
Locations
2
Primary Endpoint
Pure-tone threshold average (dB)
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this investigation is to determine the safety and preliminary efficacy of implanting a cochlear implant (CI) in the profoundly deaf ear of an adult with one normal hearing (NH) ear (termed "single-sided deaf" person, or SSD). The potential subjects will have been deafened post-lingually, thus, at one point the now deafened ear did conduct sound from the periphery. The MED-EL CI system will be implanted in ten (10) SSD patients.The long-term goal of this research program is to determine whether the CI, in combination with the NH ear, may provide improved localization ability and better speech understanding in noise, relative to performance before cochlear implantation (i.e., with the NH ear alone). A secondary long-term goal is to determine whether CI stimulation may reduce tinnitus severity, compared to tinnitus experienced prior to cochlear implantation or when the CI is turned off, after implantation.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
September 2019
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Robert Shannon
Responsible Party
Sponsor Investigator
Principal Investigator

Robert Shannon

Professor of Research, Otolaryngology - Head and Neck Surgery

University of Southern California

Eligibility Criteria

Inclusion Criteria

  • Is an adult (18 years of age or older)
  • English as the primary language
  • Able to undergo general anesthesia, as determined by physical examination and written report from the physician
  • Receives pneumovax vaccine within 2 weeks of surgery and provides documentation to the principal investigator
  • Profoundly/severely deaf in one ear ("implant ear"), as defined by:
  • 3-frequency pure-tone average≥70 dB Hearing Loss
  • Bone conduction thresholds consistent with air conduction thresholds (i.e., no conductive component to the hearing loss)
  • HINT sentence recognition score ≤40% correct, 60 dBA presentation level
  • Post-lingual onset of hearing loss, i.e., after age 6 years of age
  • Hearing loss occurred \<10 years prior, as obtained by history

Exclusion Criteria

  • Retrocochlear pathology resulting from Neurofibromatosis 2, or other types of cranial nerve/brainstem tumors
  • Co-existing medical conditions that require radiotherapy of the brainstem and/or auditory cortex
  • Any medical contraindication precluding safe administration of general anesthesia, e.g.,
  • Cardiopulmonary disease
  • Renal disease
  • Otologic conditions which contraindicate surgery
  • Active middle ear infection
  • Tympanic membrane perforation
  • Anatomic abnormalities detected on CT preventing appropriate placement of the stimulator housing in the bone of the skull or placement of the electrode array in the cochlea (e.g., ossification)
  • Psychological conditions contraindicating surgery

Outcomes

Primary Outcomes

Pure-tone threshold average (dB)

Time Frame: 6 months post-activation

Change in 3-frequency pure-tone threshold average (dB) in the normal hearing ear.

Hearing in Noise Test (signal-to-noise ratio)

Time Frame: 6 months post-activation

Change in Hearing in Noise Test signal-to-noise ratio in the normal hearing ear.

Secondary Outcomes

  • Adverse Events(1-month post-implantation)

Study Sites (2)

Loading locations...

Similar Trials